Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

542
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
542
Cancer Survival Analysis01:21

Cancer Survival Analysis

634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634
Censoring Survival Data01:09

Censoring Survival Data

511
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
511
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

547
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
547
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

388
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
388
Hazard Ratio01:12

Hazard Ratio

554
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking Nanoscale Film Properties to Electrochemical Response in Cytochrome P450 Membrane Enzyme Films.

ACS measurement science au·2026
Same author

Clinical Equivalence of a CNN-Based Automated Soft Tissue Landmark Detection System on 2D Facial Images.

Diagnostics (Basel, Switzerland)·2026
Same author

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

Future oncology (London, England)·2026
Same author

Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations.

Annals of internal medicine·2026
Same author

Incorporating the possibility of cure into network meta-analyses: A case study from resected Stage III/IV melanoma.

Research synthesis methods·2026
Same author

Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017-2023).

PloS one·2026

Related Experiment Video

Updated: Jan 11, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

Eliciting Unreported Subgroup-Specific Survival from Aggregate Randomized Controlled Trial Data.

Oguzhan Alagoz1, Prianka Singh2, Matthew Dixon2

  • 1Department of Industrial and Systems Engineering and Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, USA.

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|November 13, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces a new framework to estimate subgroup survival curves from randomized controlled trials (RCTs). The method accurately reconstructs survival data, aiding health technology assessments and meta-analyses.

Keywords:
forest plotsoptimizationrestricted-mean survivalsubgroup-specific survivalsurvival rates

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

633
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Related Experiment Videos

Last Updated: Jan 11, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

633
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Area of Science:

  • Biostatistics
  • Health Economics
  • Clinical Trial Analysis

Background:

  • Randomized controlled trials (RCTs) often lack subgroup-specific survival data, hindering detailed health technology assessments.
  • Subgroup analyses are critical for understanding treatment effects in specific patient populations.
  • Existing aggregate data limitations necessitate novel analytical approaches.

Purpose of the Study:

  • To develop and validate an analytical framework for eliciting unreported subgroup-specific survival curves from aggregate RCT data.
  • To enable subgroup-specific indirect comparisons and cost-utility analyses.
  • To improve the utility of RCT data for nuanced clinical and economic evaluations.

Main Methods:

  • Developed an optimization model assuming exponentially distributed subgroup survival durations.
  • Approximated restricted mean survival time (RMST) using a weighted average of subgroup RMSTs.
  • Incorporated hazard ratios from forest plots to link subgroup hazard rates across trial arms.
  • Validated the model on real-life oncology RCTs and synthetic datasets.

Main Results:

  • The model accurately predicted median survivals and RMSTs within 95% confidence intervals for a high percentage of subgroups in both synthetic (97%, 87%) and real-life (80%, 85%) test cases.
  • Predicted survival curves aligned with reported Kaplan-Meier curves 97% of the time in synthetic data and 71% in real-life data.
  • The framework demonstrated robust performance in reconstructing subgroup survival distributions from aggregate data.

Conclusions:

  • The proposed analytical framework provides a scalable and effective method for extracting subgroup-specific survival data from aggregate RCT results.
  • This approach facilitates subgroup-specific indirect comparisons, cost-utility analyses, and meta-analyses where such data are otherwise unavailable.
  • The study enhances the value of existing RCT data for more granular health economic and clinical research.